Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469800 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2CRHR1LMNAMEN1 | |
| SCHEMBL12756272 | 0.87 | MAPT (0.67) | MAPTSMN1; SMN2CRHR1LMNAMEN1 | |
| SCHEMBL469796 | 0.87 | MAPT (0.38) | MAPTSMN1; SMN2TSHRTDP1SLC29A1 | |
| SCHEMBL17706659 | 0.78 | MAPT (0.57) | MAPTSMN1; SMN2CRHR1TSHRTDP1 | |
| SCHEMBL428397 | 0.77 | MAPT (0.42) | MAPTSMN1; SMN2CRHR1MEN1KMT2A | |
| SCHEMBL31530718 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2CRHR1LMNAMEN1 | |
| SCHEMBL18460471 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2CRHR1LMNATSHR | |
| SCHEMBL20991400 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2CRHR1LMNATSHR | |
| SCHEMBL19982856 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2CRHR1LMNAMEN1 | |
| SCHEMBL2780687 | 0.76 | MAPT (0.50) | MAPTSMN1; SMN2CRHR1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120063976-A1 | METHODS OF REMOVING CARBON DIOXIDE AND SORBENTS FOR SAME | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120063976-A1 | METHODS OF REMOVING CARBON DIOXIDE AND SORBENTS FOR SAME | CHRM2, CHRM1, CHRM3 | MAPT 3538/4885SMN1; SMN2 1298/4885CRHR1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.